

```

chain nodes :
  19 21 22
ring nodes :
  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
chain bonds :
  2-22 11-21 13-19
ring bonds :
  1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 7-11 8-9 8-14 9-10 11-12 12-13 13-14
  13-15 14-17 14-18 15-16 16-17 17-18
exact/norm bonds :
  2-22 5-7 6-10 7-8 7-11 8-9 8-14 9-10 11-12 11-21 12-13 13-14 13-15 14-17
  14-18 15-16 16-17 17-18
exact bonds :
  13-19
normalized bonds :
  1-2 1-6 2-3 3-4 4-5 5-6
  
```

G1:O,F,Cl,Br,I

```

Match level :
  1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
  12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS 21:CLASS 22:CLASS
  
```

09/937,723

=>


Uploading 09937723.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 16:10:19 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 2028 TO ITERATE

49.3% PROCESSED 1000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

6 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 37860 TO 43260
PROJECTED ANSWERS: 34 TO 452

L2 6 SEA SSS SAM L1

=>

Uploading 09937723.str


L3 STRUCTURE UPLOADED

=> d l3

L3 HAS NO ANSWERS

L3 STR

09/937,723



G1 O, F, Cl, Br, I

Structure attributes must be viewed using STN Express query preparation.

=> s l3 sss sam

SAMPLE SEARCH INITIATED 16:14:41 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 705 TO ITERATE

100.0% PROCESSED 705 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 12508 TO 15692

PROJECTED ANSWERS: 2 TO 124

L4 2 SEA SSS SAM L3

=> s l3 sss ful

FULL SEARCH INITIATED 16:15:19 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 14537 TO ITERATE

100.0% PROCESSED 14537 ITERATIONS

16 ANSWERS

SEARCH TIME: 00.00.02

L5 16 SEA SSS FUL L3

=> s l5

L6 1 L5


=> d l6 bib,ab,hitstr

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS
 AN 2000:706441 CAPLUS
 DN 133:267019
 TI Procedure for the production of equilenin derivatives and medicaments
 containing them
 IN Schwarz, Sigfrid; Thieme, Ina; Undeutsch, Bernd; Kaufmann, Guenter;
 Roemer, Wolfgang
 PA Jenapharm G.m.b.H. und Co. K.-G., Germany
 SO Ger. Offen., 8 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19915576	A1	20001005	DE 1999-19915576	19990330
	WO 2000059922	A1	20001012	WO 2000-EP2513	20000322
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	EP 1165596	A1	20020102	EP 2000-922533	20000322
	EP 1165596	B1	20020619		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	AT 219498	E	20020715	AT 2000-922533	20000322
	JP 2002541154	T2	20021203	JP 2000-609432	20000322
PRAI	DE 1999-19915576	A	19990330		
	WO 2000-EP2513	W	20000322		
OS	CASREACT 133:267019; MARPAT 133:267019				
AB	New equilenin derivs. I (R1 = H, C1-5-alkyl, C1-5-acyl, CPh; R2 = H; R2R6 = O; R3 = H, Me; R4 = H; R4R8 = O, CH2, halomethylene, dihalomethylene; R5 = H, Me; R6 = H, F, OH, C1-5-acyloxy; R8 = OH, C1-11-acyloxy) as well as procedures for their prodn. and formulations of medicaments contg. them are described. Thus, 11.alpha.-Hydroxy-3-methoxy-14.alpha.,15.alpha.-methyleneestra-1,3,5(10)-trien-17.alpha.-yl acetate (I; R1 = Me, R2 = R8 = .beta.-H, R3 = R5 = H, R4 = .alpha.-OAc, R6 = .alpha.-OH) was prepd. from 3-Methoxy-14.alpha.,15.alpha.-methyleneestra-1,3,5(10),8-tetraen-17.alpha.-yl acetate via treatment of 11.alpha.-Hydroxy-3-methoxy-14.alpha.,15.alpha.-methylene-8.alpha.,9.alpha.-oxidoestra-1,3,5(10)-trien-17.alpha.-yl acetate with P2I4 and pyridien in CHCl3. I exhibit estrogen effectiveness and are applicable in hormone therapy with women and men.				
IT	298705-65-4P , 11.alpha.-Hydroxy-3-methoxy-14.alpha.,15.alpha.-methylene-8.alpha.,9.alpha.-oxidoestra-1,3,5(10)-trien-17.alpha.-yl acetate 298705-66-5P , 3-Methoxy-14.alpha.,15.alpha.-methylene-8.alpha.,9.alpha.-oxidoestra-1,3,5(10)-triene-11.alpha.,17.alpha.-diyl diacetate RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (prepn. of equilenin derivs. and medicaments contg. them for hormone replacement therapy)				
RN	298705-65-4	CAPLUS			
CN	Cycloprop[14,15]estra-1,3,5(10)-triene-11,17-diol, 8,9-epoxy-3',15-dihydro-				

3-methoxy-, 17-acetate, (8.alpha.,11.alpha.,14R,15.beta.,17.alpha.)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 298705-66-5 CAPLUS

CN Cycloprop[14,15]estra-1,3,5(10)-triene-11,17-diol, 8,9-epoxy-3',15-dihydro-3-methoxy-, diacetate, (8.alpha.,11.alpha.,14R,15.beta.,17.alpha.)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



IT **298705-67-6P**, 3-Methoxy-14.alpha.,15.alpha.-methyleneestra-1,3,5(10),6,8-pentaene-11.alpha.,17.alpha.-diyl diacetate
298705-68-7P, 11.alpha.-Hydroxy-3-methoxy-14.alpha.,15.alpha.-methyleneestra-1,3,5(10)-trien-17.alpha.-yl acetate **298705-69-8P**, 14.alpha.,15.alpha.-Methyleneestra-1,3,5(10),6,8-pentaene-3,11.beta.,17.beta.-triol **298705-70-1P**, 11.beta.,17.beta.-Dihydroxy-14.alpha.,15.alpha.-methyleneestra-1,3,5(10),6,8-pentaen-3-yl benzoate **298705-71-2P**, 11.beta.,17.beta.-Dihydroxy-14.alpha.,15.alpha.-methyleneestra-1,3,5(10),6,8-pentaen-3-yl propionate **298705-72-3P**, 3,11.beta.-Dihydroxy-14.alpha.,15.alpha.-methyleneestra-1,3,5(10),6,8-pentaen-17.beta.-yl decanoate **298705-73-4P**, 3,11.beta.-Dihydroxy-14.alpha.,15.alpha.-methyleneestra-1,3,5(10),6,8-pentaen-17-one **298705-74-5P**, 3-Methoxy-14.alpha.,15.alpha.-methyleneestra-1,3,5(10),6,8-pentaene-11.alpha.,17.beta.-diyl diacetate **298705-75-6P**, 15.beta.-Methyl-14.alpha.,15.alpha.-methyleneestra-1,3,5(10),6,8-pentaene-3,11.beta.,17.beta.-triol **298705-76-7P**, 11.beta.-Fluoro-14.alpha.,15.alpha.-methyleneestra-1,3,5(10),6,8-pentaene-3,17.beta.-diol **298705-77-8P**, 3,17.beta.-Dihydroxy-14.alpha.,15.alpha.-methyleneestra-1,3,5(10),6,8-pentaen-11-one **298705-78-9P**, 3-Methoxy-14.alpha.,15.alpha.-methylene-11-oxoestra-1,3,5(10),6,8-pentaen-17.alpha.-yl acetate **298705-79-0P**, 11.beta.-Hydroxy-17-(difluoromethylene)-14.alpha.,15.alpha.-methyleneestra-1,3,5(10),6,8-pentaen-3-yl benzoate **298705-80-3P**, 14.alpha.,15.alpha.:17-Bis

methyleneestra-1,3,5(10),6,8-pentaene-3,11.alpha.-diol


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of equilenin derivs. and medicaments contg. them for hormone replacement therapy)

RN 298705-67-6 CAPLUS

CN Cycloprop[14,15]estra-1,3,5,7,9-pentaene-11,17-diol, 3',15-dihydro-3-methoxy-, diacetate, (11.alpha.,14S,15.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 298705-68-7 CAPLUS

CN Cycloprop[14,15]estra-1,3,5,7,9-pentaene-11,17-diol, 3',15-dihydro-3-methoxy-, 17-acetate, (11.alpha.,14S,15.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 298705-69-8 CAPLUS

CN Cycloprop[14,15]estra-1,3,5,7,9-pentaene-3,11,17-triol, 3',15-dihydro-, (11.beta.,14S,15.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 298705-70-1 CAPLUS

CN Cycloprop[14,15]estra-1,3,5,7,9-pentaene-3,11,17-triol, 3',15-dihydro-, 3-benzoate, (11.beta.,14S,15.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 298705-71-2 CAPLUS

CN Cycloprop[14,15]estra-1,3,5,7,9-pentaene-3,11,17-triol, 3',15-dihydro-, 3-propanoate, (11.beta.,14S,15.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 298705-72-3 CAPLUS

CN Cycloprop[14,15]estra-1,3,5,7,9-pentaene-3,11,17-triol, 3',15-dihydro-, 17-decanoate, (11.beta.,14S,15.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 298705-73-4 CAPLUS

CN Cycloprop[14,15]estra-1,3,5,7,9-pentaen-17-one, 3',15-dihydro-3,11-dihydroxy-, (11.β.,14S,15.β.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 298705-74-5 CAPLUS

CN Cyclopropa[14,15]estra-1,3,5,7,9-pentaene-11,17-diol, 3',15-dihydro-3-methoxy-, diacetate, (11.α.,14S,15.β.,17.β.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 298705-75-6 CAPLUS

CN Cycloprop[14,15]estra-1,3,5,7,9-pentaene-3,11,17-triol, 3',15-dihydro-15-methyl-, (11.β.,14S,15.β.,17.β.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 298705-76-7 CAPLUS

CN Cycloprop[14,15]estra-1,3,5,7,9-pentaene-3,17-diol, 11-fluoro-3',15-dihydro-, (11.beta.,14S,15.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 298705-77-8 CAPLUS

CN Cycloprop[14,15]estra-1,3,5,7,9-pentaen-11-one, 3',15-dihydro-3,17-dihydroxy-, (14S,15.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 298705-78-9 CAPLUS

CN Cycloprop[14,15]estra-1,3,5,7,9-pentaen-11-one, 17-(acetyloxy)-3',15-dihydro-3-methoxy-, (14S,15.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 298705-79-0 CAPLUS

CN Cycloprop[14,15]estra-1,3,5,7,9-pentaene-3,11-diol, 17-(difluoromethylene)-3',15-dihydro-, 3-benzoate, (11.beta.,14R,15.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 298705-80-3 CAPLUS

CN Cycloprop[14,15]estra-1,3,5,7,9-pentaene-3,11-diol, 3',15-dihydro-17-methylene-, (11.alpha.,14R,15.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/937,723

=> d his

(FILE 'HOME' ENTERED AT 16:09:44 ON 10 DEC 2002)

FILE 'REGISTRY' ENTERED AT 16:09:49 ON 10 DEC 2002

L1 STRUCTURE UPLOADED
L2 6 S L1 SSS SAM
L3 STRUCTURE UPLOADED
L4 2 S L3 SSS SAM
L5 16 S L3 SSS FUL

FILE 'CAPLUS' ENTERED AT 16:15:28 ON 10 DEC 2002

L6 1 S L5

FILE 'CAOLD' ENTERED AT 16:16:42 ON 10 DEC 2002

=> s 15

L7 0 L5

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.38	149.09

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-0.62

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 16:16:54 ON 10 DEC 2002